Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
25
Aug 2026
Patients diagnosed with conditions after an emergency hospital admission or an emergency room visit face a higher risk of death than those diagnosed in non-emergency settings, according to a large population-based study by Emma Whitfield and colleagues from University College London, UK, published August 25th in the open access journal PLOS Medicine.
25
Aug 2026
In the years following type 2 diabetes diagnosis, women are more likely to develop mental health conditions, while men are more likely to develop cardiovascular and renal complications, according to a study published August 25th in the open access journal PLOS Medicine by Fabiola Eto from Queen Mary University of London, UK, and colleagues.
25
Aug 2026
Following the Trump administration's 2018 announcement of changes to the public charge rule that would penalize immigrants for using public benefit programs, antisanctuary counties in the US saw a 16.8-percent increase in HIV cases among Hispanic populations, compared to baseline counties.
25
Aug 2026
UMass Chan Medical School scientist Beth McCormick, PhD, and her team collaborated with researchers at the University of Bath to discover how neutrophils, the body's most abundant type of white blood cells, travel to infection sites without damaging healthy tissue.